Prof Philippe Clezardin presented his novel work on the mechanisms driving the formation of bone metastasis in breast cancer. ImageStream is a powerful device that combines the advantages of traditional analysis of heterogenous cell populations by flow cytometry with fluorescent microscopy allowing the capture of cellular changes that otherwise wouldn’t be visible. This happens in a low-cost, pocket-size portable device and has important implications in the analysis of the cancer genome.ĭr David Jamieson (Newcastle) presented the use of the ImageStream system to characterise Circulating Tumour Cells in patients with leukaemia. Nanopore sequencing allows direct DNA sequencing of long strands of nucleic acid by utilising the changes in ionic current generated as the strands of nucleic acid pass through the microscopic pores. Nanopore sequencing, introduced by Dr Andrew Beggs (Birmingham), is a ground-breaking new method to sequence DNA. In another afternoon parallel session, delegates experienced a snapshot of new cutting-edge technologies being used within the ECMC network to drive the discovery and development of new cancer treatments. New technologies and techniques in translational research – how they are supporting early phase trials Great strides were made on achieving the more detailed planning this very important work requires and on 27 June the Programme Office will hold the first writing workshop for the consensus paper. The ANM session presented further views and then focused on what the paper would contain and who would be responsible for writing and editing. It had already been decided at the earlier meeting that a consensus paper would be produced around how to effectively set up and deliver Platform Trials. The session was very well attended and heard from clinicians, patients, commercial trade associations, NHS R&D and regulators. A collaborative approach to platform trialsįollowing a very successful ECMC meeting earlier in the year where complex trials were discussed, one of the afternoon parralell sessions concentrated on Platform Trials, the term we are using to describe the various types of complex trials.

Driver evaluation program ecmc